Novavax Global Commercial Operations and COVID-19 Vaccine Update

IgG levels: Non-inferior immunogenicity of 3 lots Primary endpoint achieved* 10,000 GMFR: 2.7 GMFR: 2.6 GMFR: 2.7 1,000 100 10 Baseline Lot 1 N = 269 Day 28 Baseline Day 28 Baseline Day 28 Lot 2 N = 274 Lot 3 N = 284 Cl, confidence interval; GMT, geometric mean titer; lg, immunoglobulin; NI, non-inferiority. novavax *Equivalence was determined if the 95% Cls of GMEUS for all pairs of lots are within the pre-specified equivalence range of 0.67 to 1.5. + Validated assay conducted by Novavax Clinical Immunology1 © 2023 NOVAVAX. All rights reserved. 47

View entire presentation